Search

Your search keyword '"Liver Cirrhosis genetics"' showing total 3,817 results

Search Constraints

Start Over You searched for: Descriptor "Liver Cirrhosis genetics" Remove constraint Descriptor: "Liver Cirrhosis genetics"
3,817 results on '"Liver Cirrhosis genetics"'

Search Results

1. Elevated PRELP expression in heart and liver fibrosis promotes collagen production.

2. FoxD1 expression identifies a distinct subset of hepatic stellate cells involved in liver fibrosis.

3. Time-course RNA sequencing reveals high similarity in mRNAome between hepatic stellate cells activated by agalactosyl IgG and TGF-β1.

4. MicroRNA miR-199a-3p alleviates liver fibrosis by targeting CDK17 in activated hepatic stellate cells.

5. MIST1 regulates endoplasmic reticulum stress-induced hepatic apoptosis as a candidate marker of fatty liver disease progression.

6. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.

7. The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects.

8. Unique and Shared Molecular Mechanisms of Alcoholic and Non-Alcoholic Liver Cirrhosis Identified Through Transcriptomics Data Integration.

9. In-Depth Proteomic Analysis Reveals Phenotypic Diversity of Macrophages in Liver Fibrosis.

10. Jag1 insufficiency alters liver fibrosis via T cell and hepatocyte differentiation defects.

11. Gaudichaudione H ameliorates liver fibrosis and inflammation by targeting NRF2 signaling pathway.

12. Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.

13. New insights into potential biomarkers and their roles in biological processes associated with hepatitis C-related liver cirrhosis by hepatic RNA-seq-based transcriptome profiling.

14. Diagnostic Potential of microRNA-122 for Stage Classification in Patients with HBV-Related Cirrhosis.

15. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.

16. Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD.

17. PCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis.

18. Amniotic membrane modulates MMP9 and MMP12 gene and protein expression in experimental model of the hepatic fibrosis.

19. Precision-cut liver slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis.

20. Multi-omic analysis identifies the molecular mechanism of hepatocellular carcinoma with cirrhosis.

21. microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients.

22. Schistosoma japonicum infection-mediated downregulation of lncRNA Malat1 contributes to schistosomiasis hepatic fibrosis by the Malat1/miR-96/Smad7 pathway.

23. Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model.

24. ATF3-mediated transactivation of CXCL14 in HSCs during liver fibrosis.

25. Radiation-sensitive circRNA hsa_circ_0096498 inhibits radiation-induced liver fibrosis by suppressing EIF4A3 nuclear translocation to decrease CDC42 expression in hepatic stellate cells.

26. Small leucine zipper protein negatively regulates liver fibrosis by suppressing the expression of plasminogen activator inhibitor-1.

27. Deubiquitinase USP18 inhibits hepatic stellate cells activation and alleviates liver fibrosis via regulation of TAK1 activity.

28. A Genetically Engineered Biomimetic Nanodecoy for the Treatment of Liver Fibrosis.

29. Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models.

30. The Influence of ESR2 Gene Polymorphisms on Susceptibility to Hepatitis B Virus-Related Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma.

31. m6A epitranscriptomic and epigenetic crosstalk in liver fibrosis: Special emphasis on DNA methylation and non-coding RNAs.

32. Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension.

33. Murine HSD17β13 does not control liver steatosis and modestly impacts fibrosis in a sex- and diet-specific manner.

34. Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-β1 (TGF-β1) availability and inhibits hepatocarcinogenesis.

35. Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.

36. Evaluation of the expression of fibrosis-related genes as non-invasive diagnostic biomarkers for cirrhotic HCV-infected patients.

37. Does SLC39A8 Ala391Thr Confer Risk of Chronic Liver Disease?

38. Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis.

39. Loss of Toll-like receptor 9 protects from hepatocellular carcinoma in murine models of chronic liver disease.

41. Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation.

42. Hepatic stearoyl-CoA desaturase-1 deficiency induces fibrosis and hepatocellular carcinoma-related gene activation under a high carbohydrate low fat diet.

43. Association of CXCR4 gene expression and promoter methylation with chronic hepatitis B-related fibrosis/cirrhosis.

44. Role of WISP1 in Stellate Cell Migration and Liver Fibrosis.

45. The relationship between diverticular disease of intestine and cirrhosis: a two-sample mendelian randomization study.

46. NADPH oxidase 4 deficiency promotes hepatocellular carcinoma arising from hepatic fibrosis by inducing M2-macrophages in the tumor microenvironment.

47. The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis.

48. MicroHDF: predicting host phenotypes with metagenomic data using a deep forest-based framework.

49. YAP activation in liver macrophages via depletion of MST1/MST2 enhances liver inflammation and fibrosis in MASLD.

50. Epitranscriptomic regulation of lipid oxidation and liver fibrosis via ENPP1 mRNA m 6 A modification.

Catalog

Books, media, physical & digital resources